Regenerative medicine is where this compliance category was born. More FDA warning letters have been issued for stem cell and regen marketing than for any other healthcare vertical.
Regenerative medicine is the specialty that built the current FDA enforcement playbook on healthcare marketing. The Wellbeing Corporation $5.15M FTC settlement, the Kimera Labs case, the ongoing FDA CBER attention on HCT/P products - every major enforcement action in this category has set precedent that shapes how every regen clinic's marketing is evaluated. Our rule set started with this specialty. If RegenCompliance exists, it is because of how much enforcement happens in regenerative medicine. We are built first for regen clinics.
Active enforcement
Real FDA warning letters, FTC settlements, and state board actions shaping marketing rules for regenerative medicine clinics right now.
The Wellbeing Corporation settlement is the single most-cited FTC action in healthcare compliance training. A single Instagram post - claiming stem cells could cure arthritis, heal spinal cord injury, and reverse aging - triggered the investigation. The settlement included restitution, a 20-year compliance monitoring order, and a permanent bar on similar claims.
The FDA has issued a sustained campaign of warning letters on language implying FDA approval of HCT/P products. 'FDA-approved stem cells,' 'FDA-approved treatment,' and variations remain among the most-cited phrases in active enforcement.
HCT/P products are regulated under CBER with a specific pathway for minimal-manipulation, homologous-use products. Marketing products outside this pathway as 'minimally manipulated' or 'homologous use' - or making therapeutic claims that push the product into the 351 (drug/biologic) pathway - has produced warning letters to clinics and lab partners.
Exosome marketing has drawn particular FTC attention. Claims that exosomes 'repair,' 'regenerate,' or 'heal' tissue - standard language in exosome marketing a few years ago - are now specific enforcement targets.
Beyond FDA and FTC, state Attorneys General have used consumer protection authority to pursue regen clinics. Texas, California, and New York have each brought actions based on the intersection of state consumer protection and healthcare marketing.
Specialty-specific phrase library
Every phrase below is from real enforcement actions. RegenCompliance flags them automatically on every scan - with the compliant alternative ready.
Non-compliant
“FDA-approved stem cells”
Why: Most HCT/P products are not FDA-approved. The phrase is the single most-cited in regen enforcement.
Compliant alternative
“Performed in an FDA-registered facility using HCT/P materials under the 361 pathway”
Non-compliant
“Cures arthritis”
Why: Disease cure claim - direct FDA enforcement target going back to the 2010s.
Compliant alternative
“May support joint comfort and function for some patients”
Non-compliant
“Heals damaged tissue”
Why: Therapeutic efficacy claim that pushes product into drug-regulatory pathway.
Compliant alternative
“Some patients report improvement in function and comfort in the treated area”
Non-compliant
“Reverses aging”
Why: Cited in the Wellbeing settlement; active FTC enforcement target.
Compliant alternative
“May support aspects of skin and tissue health in the treated area”
Non-compliant
“Guaranteed results”
Why: Guarantee claim is almost never substantiable for regenerative therapies.
Compliant alternative
“Outcomes vary; we discuss realistic expectations during every consultation”
Non-compliant
“Proven to regrow cartilage”
Why: Tissue regeneration claim subject to FDA CBER scrutiny and FTC substantiation rules.
Compliant alternative
“Clinical studies on [specific protocol] have shown [specific endpoint]; patient outcomes vary”
Non-compliant
“Exosomes repair damaged cells”
Why: Current FTC target; 'repair' claims on exosomes are under active enforcement.
Compliant alternative
“Research into exosome biology continues; our current protocols use [product] for [appropriate indication]”
Non-compliant
“100% safe, no side effects”
Why: Absolute safety claim conflicts with clinical reality and substantiation rules.
Compliant alternative
“Adverse events are rare but possible; candidacy and risks are discussed at consultation”
Non-compliant
“Alternative to surgery”
Why: Comparative claim implies equivalence to surgical outcomes without substantiation.
Compliant alternative
“A non-surgical option some patients choose to explore before considering surgery”
Non-compliant
“Works for all patients”
Why: Universal efficacy claim is not substantiable for any regenerative protocol.
Compliant alternative
“May be appropriate for patients who meet specific candidacy criteria discussed at consultation”
Non-compliant
“Treats spinal cord injury”
Why: Direct disease/condition treatment claim on HCT/P products is an FDA target.
Compliant alternative
“(Remove entirely - no compliant reframe for direct spinal-cord-injury treatment claims)”
Non-compliant
“Breakthrough therapy”
Why: 'Breakthrough therapy' is a specific FDA designation; misuse is a direct flag.
Compliant alternative
“An emerging area of regenerative treatment we are offering based on current evidence”
You’ve probably said this
These are phrases regenerative medicine clinics have actually said (or considered saying). Each one triggers a specific FDA, FTC, or state board rule. Tap to see the rule and the rewrite.
On every scan
Many regen clinic service pages describe treatments using language that would push the product into the 351 (drug/biologic) pathway. Our scanner is specifically trained on the pathway distinctions - it flags language that implies the regulatory category you are not operating under.
Testimonials that name specific conditions ('my arthritis is gone,' 'I can walk again after my stem cell treatment') carry the disease claim into your marketing via the endorsement. Our scanner catches this pattern - which is what triggered several recent enforcement actions.
Staff personal accounts reposting clinic outcomes, partner content, or general regen marketing often contain language that the clinic's main website has already been cleaned up to avoid. Regulators do not distinguish between the clinic's official account and a physician's personal one.
Supplier-provided marketing assets (typically written for clinician education rather than consumer marketing) frequently contain language that the supplier itself would not use in consumer-facing channels. Our scanner catches reused supplier content with the specific problem phrases.
Internal-audience or clinician-audience content (conferences, CE-credit talks, peer presentations) uses a different standard than consumer marketing. Posting these recordings publicly without review often puts clinical-discussion language into a consumer-marketing surface, which is where compliance issues enter.
Case study
“Our revolutionary stem cell therapy cures arthritis and heals damaged tissue using FDA-approved stem cells. Exosomes repair damaged cells with 100% safe, no side effects - guaranteed results to regrow cartilage and reverse aging. Works for all patients - a proven alternative to surgery for spinal cord injury, joint pain, and chronic conditions.”
“Our regenerative medicine offerings are performed in an FDA-registered facility using HCT/P materials under the 361 pathway. Some patients report improvement in joint comfort and function in the treated area; outcomes vary and candidacy is discussed during every consultation. Adverse events are rare but possible and are reviewed at consultation. A non-surgical option some patients choose to explore before considering surgery. Clinical studies continue to inform our protocols; results depend on many factors specific to each patient.”
Outcome
Score went from 8 to 89 across 14 flagged phrases. PDF audit trail generated covering every rewrite. Every core service offering preserved - language reframed to match the 361 regulatory pathway and current FTC enforcement patterns.
Regenerative medicine is the specialty that defined this category of enforcement. More rules in our rule set come from stem cell, PRP, and exosome warning letters than from any other specialty. If you run a regen clinic, this is not a generic compliance tool you are getting - it is a compliance tool that was primarily built around your specialty, with every major enforcement action in your space already encoded as a rule.
Who uses this
Evaluating alternatives?
Tools in the platform
Regenerative Medicine Clinics-specific rule calibration. Flags disease claims, FDA misuse, and specialty-specific patterns.
Learn moreTurn flagged regenerative medicine clinics claims into compliant alternatives that preserve your voice.
Learn morePermanent evidence of your pre-publish compliance review. Regulatory-ready format.
Learn moreFAQ
Get started
Unlimited scans. 3 team seats. Founding rate $297/mo locked for life. 30-day money-back guarantee.
See compliance built for med spas, weight loss clinics, or dental practices. See all specialties
Further reading
Blog posts covering enforcement, claim categories, and tactical playbooks specifically relevant to regenerative medicine clinics.
Stem cell marketing is the single highest-risk surface in healthcare advertising. Five phrases recur in almost every multi-million-dollar settlement against a regen-med clinic. This post walks through each one, the regulatory mechanism, and a compliant rewrite that still sells.
Read articleMulti-million-dollar FTC settlements against stem cell and regenerative medicine clinics now routinely start with a single Instagram caption or Facebook testimonial. Here is how that chain actually works - and the four places clinics lose control of it.
Read articleMore than 200 FDA warning letters hit healthcare practices in 2024 - the highest volume in a quarter century. Here is what is being flagged, why regenerative medicine and med spas are on the front line, and what a defensible marketing program looks like now.
Read article